Linear regression for mean blood pressure, test for additive allele effects, subcohort without individuals on treatment for high blood pressure

Rank SNP name in MORGAM RS-code Chromosome Success Genotype N Mean coef (95% CI) nominal p-value tail-area FDR
1 2Q36_3_MG_433 rs2972147 2 98.5% C/C 747 111.234 -1.213
(-2.112, -0.314)		 0.00816 0.17934
C/T 861 112.439
T/T 249 113.377
2 2Q36_3_MG_461 rs2943634 2 97.8% A/A 225 113.512 1.170
(0.256, 2.084)		 0.01214 0.17934
A/C 850 112.408
C/C 769 111.301
3 MTHFD1L_MG_423 rs12525353 6 99.4% A/A 2 123.000 -3.823
(-6.834, -0.813)		 0.01281 0.17934
A/C 72 107.681
C/C 1801 112.252
4 SMAD3_MG_424 rs12913547 15 99.6% C/C 128 113.234 1.077
(0.091, 2.063)		 0.03224 0.33850
C/T 740 113.072
T/T 1010 111.196
5 5Q21_1_MG_455 rs383830 5 99.0% A/A 96 113.401 0.881
(-0.157, 1.919)		 0.09620 0.63090
A/T 599 112.899
T/T 1173 111.529
6 5Q21_1_MG_436 rs449650 5 99.0% G/G 1173 111.531 -0.878
(-1.916, 0.160)		 0.09720 0.63090
G/T 597 112.951
T/T 97 113.314
7 10Q11_21_MG_439 rs501120 10 96.4% C/C 47 111.138 1.008
(-0.211, 2.228)		 0.10515 0.63090
C/T 445 113.538
T/T 1327 111.706
8 5Q21_1_MG_435 rs436495 5 98.8% A/A 109 113.390 0.801
(-0.216, 1.818)		 0.12254 0.64331
A/G 655 112.977
G/G 1099 111.513
9 5Q21_1_MG_441 rs565928 5 99.5% C/C 1175 111.585 -0.741
(-1.780, 0.298)		 0.16218 0.64383
C/T 606 112.884
T/T 96 112.932
10 MIA3_MG_430 rs17465637 1 99.3% A/A 134 110.679 -0.646
(-1.620, 0.328)		 0.19347 0.64383
A/C 683 111.939
C/C 1055 112.366
11 SMAD3_MG_452 rs17228212 15 99.2% C/C 100 109.088 -0.686
(-1.725, 0.353)		 0.19569 0.64383
C/T 665 111.686
T/T 1105 112.568
12 2Q36_3_MG_447 rs7597168 2 99.4% C/C 1047 111.704 -0.639
(-1.653, 0.375)		 0.21683 0.64383
C/T 720 112.456
T/T 107 113.077
13 10Q11_21_MG_443 rs687175 10 99.5% C/C 48 111.125 0.705
(-0.471, 1.880)		 0.24013 0.64383
C/T 507 113.077
T/T 1322 111.730
14 FMN2_MG_450 rs1456648 1 98.7% G/G 45 113.489 -0.714
(-1.913, 0.486)		 0.24363 0.64383
G/T 484 111.405
T/T 1332 112.229
15 10Q11_21_MG_440 rs559580 10 99.0% C/C 48 111.125 0.695
(-0.485, 1.875)		 0.24817 0.64383
C/T 501 113.099
T/T 1318 111.713
16 10Q11_21_MG_428 rs1746048 10 99.5% C/C 1324 111.716 -0.667
(-1.846, 0.512)		 0.26750 0.64383
C/T 505 113.140
T/T 47 110.660
17 9P21_3_MG_420 rs10738610 9 99.1% A/A 628 112.186 -0.477
(-1.360, 0.406)		 0.28983 0.64383
A/C 915 112.037
C/C 326 112.168
18 10Q11_21_MG_458 rs622472 10 98.5% A/A 1303 111.757 -0.628
(-1.800, 0.544)		 0.29355 0.64383
A/C 504 113.023
C/C 50 111.010
19 10Q11_21_MG_429 rs1746049 10 99.5% C/C 1428 111.853 -0.679
(-1.970, 0.612)		 0.30264 0.64383
C/T 418 113.111
T/T 31 108.871
20 12Q12_MG_448 rs7970834 12 99.5% G/G 581 112.126 0.455
(-0.430, 1.341)		 0.31329 0.64383
G/T 949 112.575
T/T 347 110.662
21 10Q11_21_MG_456 rs513391 10 99.1% A/A 1316 111.778 -0.593
(-1.766, 0.580)		 0.32191 0.64383
A/C 504 112.988
C/C 49 110.776
22 9P21_3_MG_425 rs1333049 9 99.6% C/C 316 112.312 0.394
(-0.489, 1.277)		 0.38155 0.72841
C/G 915 111.870
G/G 647 112.246
23 1Q31_2_MG_453 rs1936982 1 99.0% C/C 237 112.047 -0.373
(-1.268, 0.521)		 0.41362 0.75531
C/T 820 111.673
T/T 811 112.434
24 SEZ6L_MG_442 rs6005015 22 99.5% C/C 167 111.784 -0.359
(-1.313, 0.594)		 0.45997 0.80495
C/T 823 111.551
T/T 887 112.622
25 SEZ6L_MG_427 rs137209 22 99.6% A/A 185 111.173 -0.332
(-1.275, 0.610)		 0.48985 0.82282
A/G 865 111.837
G/G 828 112.522
26 10Q11_21_MG_432 rs2146807 10 99.3% C/C 14 107.857 -0.513
(-2.039, 1.012)		 0.50936 0.82282
C/T 311 111.275
T/T 1547 112.295
27 PSRC1_MG_460 rs599839 1 99.5% A/A 1080 112.095 0.295
(-0.702, 1.292)		 0.56237 0.85155
A/G 679 112.124
G/G 117 110.799
28 9P21_3_MG_421 rs10757283 9 99.4% C/C 548 112.504 0.257
(-0.625, 1.140)		 0.56770 0.85155
C/T 950 111.814
T/T 376 112.084
29 9P21_3_MG_459 rs7865618 9 98.8% A/A 613 112.024 -0.139
(-1.004, 0.726)		 0.75325 0.98871
A/G 900 112.059
G/G 351 112.088
30 SEZ6L_MG_444 rs688034 22 99.5% C/C 976 112.419 -0.114
(-1.105, 0.877)		 0.82151 0.98871
C/T 769 111.723
T/T 131 111.672
31 CELSR2_MG_438 rs4970834 1 99.4% C/C 1174 111.989 0.123
(-0.954, 1.201)		 0.82262 0.98871
C/T 626 112.378
T/T 75 110.720
32 MTHFD1L_MG_449 rs12214306 6 99.2% C/C 0   0.249
(-2.617, 3.116)		 0.86474 0.98871
C/T 89 112.163
T/T 1782 112.059
33 SEZ6L_MG_457 rs6005016 22 98.9% A/A 4 113.500 -0.146
(-2.436, 2.144)		 0.90024 0.98871
A/G 128 111.570
G/G 1734 112.121
34 CELSR2_MG_434 rs413380 1 99.5% C/C 1702 112.047 -0.118
(-2.055, 1.820)		 0.90515 0.98871
C/T 165 112.239
T/T 10 114.650
35 19Q12_MG_446 rs7250581 19 97.9% A/A 46 113.163 0.071
(-1.157, 1.300)		 0.90956 0.98871
A/G 430 111.980
G/G 1371 112.159
36 SMAD3_MG_431 rs1866317 15 99.5% C/C 30 114.783 -0.054
(-1.329, 1.222)		 0.93445 0.98871
C/G 453 112.045
G/G 1394 112.034
37 SEZ6L_MG_426 rs137205 22 99.5% A/A 144 111.997 0.040
(-0.933, 1.013)		 0.93604 0.98871
A/G 806 111.854
G/G 926 112.335
38 9P21_3_MG_451 rs1537378 9 98.1% A/A 282 111.833 -0.014
(-0.907, 0.879)		 0.97571 0.98871
A/G 892 112.128
G/G 676 112.137
39 9P21_3_MG_437 rs496892 9 99.0% C/C 479 111.857 0.013
(-0.859, 0.885)		 0.97719 0.98871
C/T 951 112.412
T/T 437 111.723
40 MIA3_MG_454 rs3008621 1 98.5% A/A 47 112.362 0.015
(-1.202, 1.232)		 0.98045 0.98871
A/G 443 112.597
G/G 1368 111.934
41 MTHFD1L_MG_445 rs6922269 6 99.3% A/A 99 111.396 0.012
(-1.019, 1.043)		 0.98158 0.98871
A/G 665 111.755
G/G 1109 112.332
42 19Q12_MG_422 rs11670734 19 99.5% C/C 142 111.137 0.007
(-0.967, 0.981)		 0.98871 0.98871
C/G 759 111.983
G/G 976 112.297

adjusted for: cohort age1 sex

Updated on 2008-12-08